<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00472758</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP145</org_study_id>
    <nct_id>NCT00472758</nct_id>
  </id_info>
  <brief_title>A Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose for MEDI-545</brief_title>
  <acronym>CP145</acronym>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation, Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose, Intravenously Administered MEDI-545, a Fully Human Anti-Interferon-Alpha Monoclonal Antibody, in Patients With Chronic Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -To evaluate the safety and tolerability of a multiple doses of this drug in adult patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -The primary objective of the study is to evaluate the safety and tolerability of escalating&#xD;
      single IV doses of MEDI-545 in adult patients with chronic plaque psoriasis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of MEDI-545 will be assessed through the collection of AEs and SAEs from study drug administration through Study Day 126.</measure>
    <time_frame>Through day 26</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoints are the PK and IM of single-dose IV MEDI-545.</measure>
    <time_frame>determination not stated</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Chronic Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MEDI 545</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI 545</intervention_name>
    <description>IV dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV Placebo dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female adults, age 18 through 70 years of age at time of screening;&#xD;
&#xD;
          -  Written informed consent obtained from the patient prior to receipt of any study&#xD;
             medication or beginning study procedures;&#xD;
&#xD;
          -  Documented clinical history of chronic plaque psoriasis;&#xD;
&#xD;
          -  ≥ 3% body surface area (BSA) involvement in affected skin other than the face and&#xD;
             scalp;&#xD;
&#xD;
          -  Have at least two target plaques that are suitable for serial photographic&#xD;
             assessments, one of which is of a size and location to allow serial biopsies;&#xD;
&#xD;
          -  No significant changes in regular psoriasis treatment from at least 28 days from&#xD;
             screening through the time of study drug administration;&#xD;
&#xD;
          -  Sexually active women, unless surgically sterile or at least 1 year post-menopausal,&#xD;
             must use an effective method of avoiding pregnancy (including oral, transdermal, or&#xD;
             implanted contraceptives, intrauterine device, female condom with spermicide,&#xD;
             diaphragm with spermicide, cervical cap, abstinence, use of a condom with spermicide&#xD;
             by the sexual partner or sterile sexual partner) for 21 days prior to study drug&#xD;
             administration, and must agree to continue using such precautions through Study Day&#xD;
             126. Cessation of birth control after this point should be discussed with a&#xD;
             responsible physician. Sexually active men, unless surgically sterile, must likewise&#xD;
             use an effective method of birth control (condom with spermicide) and must agree to&#xD;
             continue using such precautions through Study Day 126;&#xD;
&#xD;
          -  Willing to forego other forms of experimental treatment and study procedures during&#xD;
             the study; and&#xD;
&#xD;
          -  Ability to complete the study period, including follow-up period through Study Day&#xD;
             126.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of MEDI-545 in any previous clinical study;&#xD;
&#xD;
          -  History of allergy or reaction to any component of the MEDI-545 formulation;&#xD;
&#xD;
          -  Pustular, guttate, or erythrodermic psoriasis as the predominant disease type;&#xD;
&#xD;
          -  Current use of potent topical corticosteroids, tacrolimus, or calcipotriol from 28&#xD;
             days prior to screening through study drug administration;&#xD;
&#xD;
          -  Current use of phototherapy including tanning beds, Goeckerman or modified Goeckerman&#xD;
             regimen, systemic corticosteroids, cyclosporin A, azathioprine, mycophenolate mofetil,&#xD;
             methotrexate, or any other systemic treatment for psoriasis within 28 days prior to&#xD;
             screening up through study drug administration;&#xD;
&#xD;
          -  Current use of biologic agents such as alefacept or tumor necrosis factor-α inhibitors&#xD;
             within 90 days prior to screening up through study drug administration;&#xD;
&#xD;
          -  Any disease or illness, other than chronic plaque psoriasis, that may require the use&#xD;
             of systemic corticosteroids during the study period;&#xD;
&#xD;
          -  Acute illnesses or evidence of significant active infection, such as fever ≥ 38.0°C (≥&#xD;
             100.5°F) from screening through study drug administration;&#xD;
&#xD;
          -  Receipt of any investigational drug therapy or attenuated live vaccine therapy (other&#xD;
             than vaccination against influenza) within 30 days or 5 half-life periods (whichever&#xD;
             is longer) prior to study drug administration through the end of study;&#xD;
&#xD;
          -  Pregnancy (sexually active women, unless surgically sterile or at least 1 year&#xD;
             post-menopausal, must have a negative serum pregnancy test at screening and a negative&#xD;
             urine pregnancy test prior to study drug administration on Study Day 0);&#xD;
&#xD;
          -  Breastfeeding or lactating women;&#xD;
&#xD;
          -  Evidence of infection with hepatitis B or C virus, or human immunodeficiency virus&#xD;
             (HIV)-1 or -2, or active infection with hepatitis A, as determined by results of&#xD;
             testing at screening;&#xD;
&#xD;
          -  A history of severe infection with cytomegalovirus or viruses of the herpes family&#xD;
             including Epstein-Barr virus requiring hospitalization, disseminated herpes, herpes&#xD;
             encephalitis, or ophthalmic herpes;&#xD;
&#xD;
          -  Herpes zoster within 3 months prior to screening;&#xD;
&#xD;
          -  Current suppressive antiviral therapy for herpes or other viral infections;&#xD;
&#xD;
          -  A history of cancer except basal cell carcinoma or in situ carcinoma of the cervix&#xD;
             treated with apparent success with curative therapy ≥ 1 year prior to randomization;&#xD;
&#xD;
          -  Elective surgery planned during the study period through end of study;&#xD;
&#xD;
          -  Clinically significant abnormality, as determined by the investigator, on 12-lead&#xD;
             electrocardiogram (ECG) or chest radiograph at screening;&#xD;
&#xD;
          -  A history of coagulation disorders;&#xD;
&#xD;
          -  History of primary immunodeficiency;&#xD;
&#xD;
          -  History of stroke, or any cerebrovascular disease requiring current&#xD;
             medication/treatment;&#xD;
&#xD;
          -  In the opinion of the investigator, clinically significant active cardiac disease,&#xD;
             including: unstable angina; myocardial infarction within 6 months; congestive heart&#xD;
             failure; or arrhythmia requiring active therapy;&#xD;
&#xD;
          -  Ongoing, clinically significant (in the opinion of the investigator) chronic&#xD;
             infectious disease;&#xD;
&#xD;
          -  History of active tuberculosis or positive tuberculosis (TB) test (defined as a&#xD;
             reaction ≥ 10 mm in diameter) without a completed course of appropriate medical&#xD;
             treatment;&#xD;
&#xD;
          -  At the time of screening, any of the following: clinically significant abnormalities&#xD;
             of hemoglobin, total white blood cell count, or platelet count; aspartate transaminase&#xD;
             (AST) or alanine transaminase (ALT) &gt; 1.5 times the upper limits of normal (ULN),&#xD;
             serum creatinine, and prothrombin time (PT) or partial thromboplastin time (PTT) &gt;&#xD;
             ULN;&#xD;
&#xD;
          -  Any other abnormal laboratory values in the screening panel that, in the opinion of&#xD;
             the investigator, are clinically significant. Abnormal results on screening laboratory&#xD;
             tests may be repeated once at the discretion of the site investigator(s) or qualified&#xD;
             designee, prior to Study Day 0, to determine eligibility; or&#xD;
&#xD;
          -  Evidence of any systemic disease or skin disease (other than chronic plaque&#xD;
             psoriasis), any finding upon physical examination or history of any disease that, in&#xD;
             the opinion of the investigator, designated health care provider, or medical monitor,&#xD;
             may compromise the safety of the patient in the study or confound the analysis of the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara White, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Innovaderm Research, Laval, Inc.</name>
      <address>
        <city>Laval-Quebec</city>
        <zip>H7S 2C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research, Inc.</name>
      <address>
        <city>Montreal</city>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Probity Medical Research</name>
      <address>
        <city>Waterloo- Ontario</city>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>May 11, 2007</study_first_submitted>
  <study_first_submitted_qc>May 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2007</study_first_posted>
  <last_update_submitted>November 16, 2011</last_update_submitted>
  <last_update_submitted_qc>November 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sifalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

